What is the current valuation of the market as of 2024?

The Veterinary Diagnostics Market was valued at 3.356 USD Billion in 2024. Read More

What is the projected market size for the market by 2035?

The market is projected to reach 11.12 USD Billion by 2035. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the Veterinary Diagnostics Market during the forecast period 2025 - 2035 is 11.5%. Read More

Which companies are considered key players in the Veterinary Diagnostics Market?

Key players in the market include Idexx Laboratories, Zoetis, Thermo Fisher Scientific, and Heska Corporation. Read More

What are the main product segments in the market?

The main product segments include Consumables, Reagents & Kits, and Instruments & Devices. Read More

How does the market performance vary across different species in the Veterinary Diagnostics Market?

The market performance varies, with Canine diagnostics projected to grow from 1.2 to 3.5 USD Billion by 2035. Read More

What types of testing are included in the market?

Testing types include Analytical Services, Diagnostic Imaging, and Molecular Diagnostics, among others. Read More

What are the primary disease types addressed in the market?

Primary disease types include Infectious Diseases, Non-Infectious Diseases, and Hereditary conditions. Read More

What are the end-use segments in the Veterinary Diagnostics Market?

End-use segments encompass Laboratories, Veterinary Hospitals and Clinics, and Point-of-Care/In-House Testing. Read More

What is the growth potential for the market in the coming years?

The market appears to have substantial growth potential, with a projected increase to 11.12 USD Billion by 2035. Read More

Veterinary Diagnostics Market

ID: MRFR/LS/20131-HCR

128 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Veterinary Diagnostics Market Research Report: Size, Share, Trend Analysis By Product (Consumables, Reagents & Kits and Instruments & Devices), By Species (Cattle, Canine, Feline, Caprine, Equine, Ovine, Porcine, Avian, and Others), By Testing Type (Analytical Services, Diagnostic Imaging, Bacteriology, Pathology, Molecular Diagnostics, Immunoassays, Parasitology, Serology, and Virology), By Disease Type (Infectious Diseases, Non-Infectious Diseases, Hereditary, Congenital and Acquired Diseases, General Ailments, and Structural & Functional Diseases), By End-Use (Laboratories, Veterinary Hospitals & Clinics, Point-Of-Care/In-House Testing, and Research Institutes & Universities) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Veterinary Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Product (USD Billion) | |
  1. 4.1.1 Consumables | |
  2. 4.1.2 Reagents & Kits | |
  3. 4.1.3 Instruments & Devices |
2. 4.2 Healthcare, BY Species (USD Billion) | |
  1. 4.2.1 Cattle | |
  2. 4.2.2 Canine | |
  3. 4.2.3 Feline | |
  4. 4.2.4 Caprine | |
  5. 4.2.5 Equine | |
  6. 4.2.6 Ovine | |
  7. 4.2.7 Porcine | |
  8. 4.2.8 Avian | |
  9. 4.2.9 Others |
3. 4.3 Healthcare, BY Testing Type (USD Billion) | |
  1. 4.3.1 Analytical Services | |
  2. 4.3.2 Diagnostic Imaging | |
  3. 4.3.3 Bacteriology | |
  4. 4.3.4 Pathology | |
  5. 4.3.5 Molecular Diagnostics | |
  6. 4.3.6 Immunoassays | |
  7. 4.3.7 Parasitology | |
  8. 4.3.8 Serology | |
  9. 4.3.9 Virology |
4. 4.4 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.4.1 Infectious Diseases | |
  2. 4.4.2 Non-Infectious Diseases | |
  3. 4.4.3 Hereditary | |
  4. 4.4.4 Congenital & Acquired Diseases | |
  5. 4.4.5 General Ailments | |
  6. 4.4.6 Structural & Functional Diseases |
5. 4.5 Healthcare, BY End-Use (USD Billion) | |
  1. 4.5.1 Laboratories | |
  2. 4.5.2 Veterinary Hospitals and Clinics | |
  3. 4.5.3 Point-of-Care/In-House Testing | |
  4. 4.5.4 Research Institutes and Universities |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Idexx Laboratories (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Zoetis (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Thermo Fisher Scientific (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Heska Corporation (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Neogen Corporation (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Virbac (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Boehringer Ingelheim (DE) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Randox Laboratories (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 EIKEN Chemical (JP) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY PRODUCT |
7. 6.4 US MARKET ANALYSIS BY SPECIES |
8. 6.5 US MARKET ANALYSIS BY TESTING TYPE |
9. 6.6 US MARKET ANALYSIS BY DISEASE TYPE |
10. 6.7 US MARKET ANALYSIS BY END-USE |
11. 6.8 CANADA MARKET ANALYSIS BY PRODUCT |
12. 6.9 CANADA MARKET ANALYSIS BY SPECIES |
13. 6.10 CANADA MARKET ANALYSIS BY TESTING TYPE |
14. 6.11 CANADA MARKET ANALYSIS BY DISEASE TYPE |
15. 6.12 CANADA MARKET ANALYSIS BY END-USE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY PRODUCT |
18. 6.15 GERMANY MARKET ANALYSIS BY SPECIES |
19. 6.16 GERMANY MARKET ANALYSIS BY TESTING TYPE |
20. 6.17 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
21. 6.18 GERMANY MARKET ANALYSIS BY END-USE |
22. 6.19 UK MARKET ANALYSIS BY PRODUCT |
23. 6.20 UK MARKET ANALYSIS BY SPECIES |
24. 6.21 UK MARKET ANALYSIS BY TESTING TYPE |
25. 6.22 UK MARKET ANALYSIS BY DISEASE TYPE |
26. 6.23 UK MARKET ANALYSIS BY END-USE |
27. 6.24 FRANCE MARKET ANALYSIS BY PRODUCT |
28. 6.25 FRANCE MARKET ANALYSIS BY SPECIES |
29. 6.26 FRANCE MARKET ANALYSIS BY TESTING TYPE |
30. 6.27 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
31. 6.28 FRANCE MARKET ANALYSIS BY END-USE |
32. 6.29 RUSSIA MARKET ANALYSIS BY PRODUCT |
33. 6.30 RUSSIA MARKET ANALYSIS BY SPECIES |
34. 6.31 RUSSIA MARKET ANALYSIS BY TESTING TYPE |
35. 6.32 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
36. 6.33 RUSSIA MARKET ANALYSIS BY END-USE |
37. 6.34 ITALY MARKET ANALYSIS BY PRODUCT |
38. 6.35 ITALY MARKET ANALYSIS BY SPECIES |
39. 6.36 ITALY MARKET ANALYSIS BY TESTING TYPE |
40. 6.37 ITALY MARKET ANALYSIS BY DISEASE TYPE |
41. 6.38 ITALY MARKET ANALYSIS BY END-USE |
42. 6.39 SPAIN MARKET ANALYSIS BY PRODUCT |
43. 6.40 SPAIN MARKET ANALYSIS BY SPECIES |
44. 6.41 SPAIN MARKET ANALYSIS BY TESTING TYPE |
45. 6.42 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
46. 6.43 SPAIN MARKET ANALYSIS BY END-USE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY PRODUCT |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY SPECIES |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TESTING TYPE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY END-USE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY PRODUCT |
54. 6.51 CHINA MARKET ANALYSIS BY SPECIES |
55. 6.52 CHINA MARKET ANALYSIS BY TESTING TYPE |
56. 6.53 CHINA MARKET ANALYSIS BY DISEASE TYPE |
57. 6.54 CHINA MARKET ANALYSIS BY END-USE |
58. 6.55 INDIA MARKET ANALYSIS BY PRODUCT |
59. 6.56 INDIA MARKET ANALYSIS BY SPECIES |
60. 6.57 INDIA MARKET ANALYSIS BY TESTING TYPE |
61. 6.58 INDIA MARKET ANALYSIS BY DISEASE TYPE |
62. 6.59 INDIA MARKET ANALYSIS BY END-USE |
63. 6.60 JAPAN MARKET ANALYSIS BY PRODUCT |
64. 6.61 JAPAN MARKET ANALYSIS BY SPECIES |
65. 6.62 JAPAN MARKET ANALYSIS BY TESTING TYPE |
66. 6.63 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
67. 6.64 JAPAN MARKET ANALYSIS BY END-USE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY PRODUCT |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY SPECIES |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TESTING TYPE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY END-USE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY PRODUCT |
74. 6.71 MALAYSIA MARKET ANALYSIS BY SPECIES |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TESTING TYPE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
77. 6.74 MALAYSIA MARKET ANALYSIS BY END-USE |
78. 6.75 THAILAND MARKET ANALYSIS BY PRODUCT |
79. 6.76 THAILAND MARKET ANALYSIS BY SPECIES |
80. 6.77 THAILAND MARKET ANALYSIS BY TESTING TYPE |
81. 6.78 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
82. 6.79 THAILAND MARKET ANALYSIS BY END-USE |
83. 6.80 INDONESIA MARKET ANALYSIS BY PRODUCT |
84. 6.81 INDONESIA MARKET ANALYSIS BY SPECIES |
85. 6.82 INDONESIA MARKET ANALYSIS BY TESTING TYPE |
86. 6.83 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
87. 6.84 INDONESIA MARKET ANALYSIS BY END-USE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY PRODUCT |
89. 6.86 REST OF APAC MARKET ANALYSIS BY SPECIES |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TESTING TYPE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
92. 6.89 REST OF APAC MARKET ANALYSIS BY END-USE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY PRODUCT |
95. 6.92 BRAZIL MARKET ANALYSIS BY SPECIES |
96. 6.93 BRAZIL MARKET ANALYSIS BY TESTING TYPE |
97. 6.94 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
98. 6.95 BRAZIL MARKET ANALYSIS BY END-USE |
99. 6.96 MEXICO MARKET ANALYSIS BY PRODUCT |
100. 6.97 MEXICO MARKET ANALYSIS BY SPECIES |
101. 6.98 MEXICO MARKET ANALYSIS BY TESTING TYPE |
102. 6.99 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
103. 6.100 MEXICO MARKET ANALYSIS BY END-USE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY PRODUCT |
105. 6.102 ARGENTINA MARKET ANALYSIS BY SPECIES |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TESTING TYPE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
108. 6.105 ARGENTINA MARKET ANALYSIS BY END-USE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY SPECIES |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TESTING TYPE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY SPECIES |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TESTING TYPE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY SPECIES |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TESTING TYPE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY PRODUCT |
126. 6.123 REST OF MEA MARKET ANALYSIS BY SPECIES |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TESTING TYPE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
129. 6.126 REST OF MEA MARKET ANALYSIS BY END-USE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY PRODUCT, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY SPECIES, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY SPECIES, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY TESTING TYPE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TESTING TYPE, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY END-USE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY END-USE, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY END-USE, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY END-USE, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY END-USE, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY END-USE, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY END-USE, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY END-USE, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY END-USE, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY END-USE, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY END-USE, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY END-USE, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY END-USE, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY END-USE, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY END-USE, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY END-USE, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY END-USE, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY END-USE, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY END-USE, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY END-USE, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY END-USE, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY END-USE, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY END-USE, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY END-USE, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY END-USE, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY END-USE, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY END-USE, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY END-USE, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY END-USE, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY PRODUCT, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TESTING TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY END-USE, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Product (USD Billion, 2025-2035)

Consumables
Reagents & Kits
Instruments & Devices

Healthcare By Species (USD Billion, 2025-2035)

Cattle
Canine
Feline
Caprine
Equine
Ovine
Porcine
Avian
Others

Healthcare By Testing Type (USD Billion, 2025-2035)

Analytical Services
Diagnostic Imaging
Bacteriology
Pathology
Molecular Diagnostics
Immunoassays
Parasitology
Serology
Virology

Healthcare By Disease Type (USD Billion, 2025-2035)

Infectious Diseases
Non-Infectious Diseases
Hereditary
Congenital & Acquired Diseases
General Ailments
Structural & Functional Diseases

Healthcare By End-Use (USD Billion, 2025-2035)

Laboratories
Veterinary Hospitals and Clinics
Point-of-Care/In-House Testing
Research Institutes and Universities

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓